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Abstract 
Hypoxia commonly occurs within tumours and is a major cause of radiotherapy resistance. 
Clinical outcomes could be improved by locating and selectively increasing the dose 
delivered to hypoxic regions. Here we describe a miniature implantable sensor for real-time 
monitoring of tissue oxygenation that could enable this novel treatment approach to be 
implemented. The sensor uses a solid-state electrochemical cell that was microfabricated at 
wafer level on a silicon substrate, and includes an integrated reference electrode and 
electrolyte membrane. It gave a linear response to oxygen concentration, and was unaffected 
by sterilisation and irradiation, but showed susceptibility to biofouling. Oxygen selectivity 
was also evaluated against various clinically relevant electroactive compounds. We 
investigated its robustness and functionality under realistic clinical conditions using a sheep 
model of lung cancer. The sensor remained functional following CT-guided tumour 
implantation, and was sufficiently sensitive to track acute changes in oxygenation within 
tumour tissue. 
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1. Introduction  1 
Hypoxia commonly occurs within solid tumours due to disorganised growth of blood vessels. 2 
It is often spatially heterogeneous and can change with time [1, 2]. Unfortunately hypoxia 3 
also causes resistance to radiotherapy, with cancer cells in low oxygen environments able to 4 
withstand radiation doses 2 – 3 times higher than aerobic cells [3]. Hypoxia is also associated 5 
with malignant progression and poor clinical outcome [4]. Knowledge of the location and 6 
degree of hypoxia within a tumour could therefore be used to personalise and improve 7 
radiotherapy by matching the dose distribution to treatment sensitivity – a concept known as 8 
“dose painting” [5]. This has the potential to improve cancer treatment by optimising its 9 
effectiveness while minimising side effects. Advanced techniques for achieving the necessary 10 
precise dose delivery such as Intensity Modulated Radiotherapy are already in widespread 11 
use [6], but there is no clinically applicable technique for continuous real-time measurement 12 
of tumour hypoxia.  13 
 14 
Existing medical imaging techniques that can measure tumour hypoxia, such as positron 15 
emission tomography (PET) and magnetic resonance imaging, provide only qualitative 16 
measurements, have limited spatial resolution, and give only a single time-point, limiting 17 
their usefulness [7]. In addition, PET scans result in radiation exposure, limiting the 18 
frequency with which they can be safely used. Quantitative imaging of hypoxia using 19 
electron paramagnetic resonance imaging is under development, but will require advances in 20 
readout technologies and the use of probe compounds that are not currently approved for use 21 
in humans [8]. Direct measurement of oxygen within tumours is possible using the Eppendorf 22 
polarographic needle electrode. This is a transcutaneous electrochemical sensor that can be 23 
mechanically stepped through tissue along a linear track to measure hypoxia. It has been used 24 
extensively in research settings [9], but is not clinically applicable as it requires an invasive 25 
procedure for each measurement and again only gives single time-point measurements. 26 
 27 
To overcome these limitations and deliver continuous real-time sensing for personalised 28 
radiotherapy treatment, we have developed and tested a miniature implantable sensor that 29 
could be inserted into multiple regions of a tumour. This would enable the construction of a 30 
real-time hypoxia map, allowing personalised adaptations to radiotherapy dose distribution 31 
during a course of treatment (Fig. 1) [10]. This type of implantable sensor was seen as 32 
acceptable by the majority cancer patients we recently surveyed [11]. 33 
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The sensor is based on electrochemical oxygen detection. This is the simplest method of 34 
measuring oxygen concentration and was first described in 1897 by Danneel and Nernst [12]. 35 
Following their discovery, a series of innovations culminated in the “Clark electrode” oxygen 36 
sensor in 1956, which can reliably operate in biological media [13]. The Clark electrode is an 37 
amperometric sensor, detecting oxygen at a platinum electrode via a reduction reaction that 38 
produces a current proportional to the oxygen concentration [14]. A key development was 39 
separation of its bare electrodes and their liquid electrolyte from external biological media 40 
using a gas permeable membrane. This prevents dissolved proteins and metabolites from 41 
interfering with the electrode and impairing its ability to sense oxygen [15]. However, 42 
conventional Clark electrode sensors are still typically unsuitable for implantation as they are 43 
bulky and contain a liquid electrolyte. To overcome these problems, we have developed a 44 
miniature Clark-type oxygen sensor that is specifically designed for implantation. Silicon 45 
based microfabrication techniques were used throughout the sensor fabrication process, as 46 
they allow straightforward miniaturisation, excellent reproducibility, and low manufacturing 47 
cost in volume. Crucially, they also open the possibility of future integration with 48 
complementary metal-oxide-semiconductor (CMOS) instrumentation electronics. 49 
 50 
The miniature sensor is based on a three-electrode cell, with a platinum working electrode 51 
(WE) at which oxygen reduction occurs, a Ag/AgCl reference electrode (RE) that provides a 52 
fixed electrochemical potential against which the WE potential can be accurately set, and a 53 
platinum counter electrode (CE). We selected a Ag/AgCl RE because it is well tested in 54 
biosensing applications and is more straightforward to miniaturise than other standard REs 55 
[16]. The sensor surface is coated with a thin-film of the porous ionomer Nafion that allows 56 
transport of water and protons [17], combining the functions of both an electrolyte matrix and 57 
membrane into a single layer. This enables the device to be fully solid-state. Several other 58 
designs of microfabricated electrochemical oxygen sensors have previously been described 59 
[18-31], highlighting the broad interest in this technology. However, to date no design has 60 
been reported that is not only amenable to wafer-level CMOS post-processing, and integrated 61 
with a stable on-chip RE and membrane, but also successfully validated in an implantable 62 
application. Here we describe the microfabrication and testing of a sensor platform that meets 63 
all these criteria, and show proof-of-principle operation within an ovine lung tumour. 64 
 65 
 66 
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2. Material and methods 67 
2.1. Electrode fabrication 68 
Sensors were fabricated on 100 mm diameter, n-type, <100> orientation silicon wafers 69 
(Si-Mat). A bottom insulator layer of 500 nm silicon dioxide was grown by thermal 70 
oxidation. Electrodes and interconnect were fabricated from a layer of 50 nm Pt on top of a 71 
10 nm Ti adhesion layer, both deposited by electron beam evaporation, patterned using 72 
photolithography, and etched in Ar plasma. A 1000 nm layer of aluminium was sputtered 73 
onto the surface and patterned using a lift-off process to form bond pads. The wafer surface 74 
was passivated with 500 nm of silicon nitride, followed by 250 nm of silicon dioxide to 75 
promote adhesion of the Nafion membrane [32]. Both passivation layers were deposited 76 
using high-frequency plasma enhanced chemical vapour deposition. Openings to the 77 
electrode and bond pad areas were then defined in the passivation by photolithography and 78 
subsequent processing in a CHF3 / Ar plasma (to etch silicon dioxide) followed by CF4 / O2 79 
plasma (to etch silicon nitride). For the RE, early testing showed that bare platinum did not 80 
produce a sufficiently consistent potential, so instead we used an additional Ag/AgCl layer on 81 
the RE surface to provide a fixed and stable electrochemical potential. A 500 nm layer of 82 
silver was deposited by electron beam evaporation and patterned over the RE area using a 83 
lift-off process. To chloridise the silver, a protective layer of photoresist was first deposited 84 
over the aluminium bond pads to prevent their oxidation, and then the wafer was dipped in 85 
50 mM aqueous FeCl3 for 60 s at room temperature, which deposited a solid layer of AgCl on 86 
the RE surface. After chloridisation the protective photoresist was removed by wet stripping. 87 
 88 
2.2. Nafion membrane stack fabrication 89 
 90 
The Nafion membrane was designed to cover all three electrodes, as it has previously been 91 
shown to generally reduce electrode biofouling [33, 34] and to extend Ag/AgCl RE lifetime 92 
[35]. We found that microfabrication of Nafion structures was challenging, as the layer was 93 
easily damaged during wafer processing and packaging. We therefore developed a novel 94 
method to deposit and protect it during these steps. The wafer surface was first treated in a 95 
solution of 2% Silane A174 (3-(Trimethoxysilyl)propyl methacrylate) in ethanol for 5 min at 96 
room temperature to promote Nafion adhesion [23, 28], then dried at 60 ˚C for 30 min. A 97 
solution of 5% Nafion in lower aliphatic alcohols and water (274704, Sigma-Aldrich) was 98 
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then spin coated onto the wafer at 150 rpm for 10 s, followed by 500 rpm for a further 30 s. 99 
The layer was air dried at room temperature and annealed at 120 ˚C for 5 min on a hotplate. 100 
SPR350 photoresist (Dow) was deposited by spin coating at 1000 rpm for 60 s, soft-baked at 101 
90 ˚C for 90 s, patterned using photolithography to define the membrane area, and then 102 
developed for 1 min. An MF-26A developer solution (Dow) diluted to 2:1 (developer : water) 103 
was used to prevent attack of the Nafion surface [32]. The Nafion was etched in O2 plasma, 104 
and the photoresist was left in place following etching as an over-etch buffer for later steps 105 
(Fig. S1a). Finally, to provide solvent resistance, a temporary protective layer of 500 nm 106 
Parylene-C was deposited by chemical vapour deposition, patterned using photolithography 107 
to cover the Nafion layer, and etched in O2 plasma (Fig. S1b). Together these layers protected 108 
the Nafion from vigorous cleaning processes during packaging. The final membrane was 109 
characterised using a DektakXT surface profiler on test dies from which the protective layers 110 
had been stripped. 111 
 112 
2.3. Sensor packaging 113 
 114 
Sensors were diced into 2 mm × 3 mm chips and mounted on the end of a custom six-track 115 
flexible PCB (Merlin Flex Ltd) using Loctite 4014 biocompatible adhesive. The flexible PCB 116 
had dimensions of 1.7 mm × 200 mm (for bench testing) or 1.7 mm × 500 mm (for sheep 117 
implantation). Connections from the sensor bond pads to the flexible PCB were made using 118 
gold wire bonds. Bonds were made from each pad to two adjacent tracks on the PCB, 119 
allowing verification of the pad connection after implantation by testing electrical continuity 120 
between the tracks. The sensor assembly was encapsulated in OG116-31 photocurable 121 
biocompatible epoxy (Epoxy Technology, Inc.) that was selectively cured by exposure to 122 
ultraviolet (UV) light to form a hermetic package around the die and bonds. The external 123 
dimensions were approximately 2.8 mm × 5.1 mm × 1.4 mm (W × L × H), and an unexposed 124 
region approximately 1.4 mm × 1.8 mm was left over the sensor active area. The packaging 125 
dimensions were designed to be compatible with delivery through an 8G Jamshidi needle. 126 
Unexposed epoxy was manually removed from the outside of the package and internal sensor 127 
area using acetone. Epoxy was then deposited on the back of the sensor and cured by flood 128 
UV exposure. Following encapsulation, the protective Parylene-C layer on the sensor die 129 
surface was removed using O2 plasma etching, and the photoresist layer on the Nafion was 130 
removed by dipping in MF-26A developer for 10 - 15 s, followed by immersion in water 131 
(Fig. S1c). Finally, the epoxy encapsulation was heat cured at 80 ˚C for 2 h to ensure 132 
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biocompatibility and maximum mechanical strength. The flexible PCB was connected to 133 
potentiostat instrumentation through a miniature edge connector (XF3M-0615-1B-R100, 134 
Omron). 135 
 136 
2.4. Scanning electron microscopy and focused ion beam milling 137 
 138 
The RE surface was inspected during fabrication using a Tescan Vega3 XMU scanning 139 
electron microscope. Surface composition was characterised using an energy dispersive X-140 
ray spectroscopy detector at 12.5 kV beam energy over a 10 µm × 7.5 µm field. For each 141 
sampled area, 1×105 counts were analysed using Bruker EDS software. Die cross-sections 142 
were milled using a FEI Strata 200XP focussed ion beam system with a 30 kV gallium beam. 143 
Milled die samples were coated in a thin layer of evaporated gold to protect the polymer 144 
layers prior to imaging. 145 
 146 
2.5. Electrochemical characterisation 147 
 148 
An Autolab PGSTAT12 bench potentiostat (Metrohm AG), controlled using Nova software, 149 
was used for sensor characterisation. For stability and lifetime testing a MUX.MULTI4 150 
multiplexer (Metrohm AG) was also used to allow sequential measurement of the sensor RE 151 
potential and WE current. CV measurements were performed using a 2 mV step size and 152 
100 mV/s scan rate. All reagents used for electrochemical characterisation of sensors were 153 
obtained from Sigma-Aldrich, and were used as received. Chemical permeability testing of 154 
the Nafion membrane was performed in a solution of 1 mM K3[Fe(CN)6], 1 mM 155 
K4[Fe(CN)6], and 100 mM KCl. Sensor performance was measured in phosphate buffered 156 
saline (PBS) containing 154 mM NaCl and 10 mM phosphate buffer at pH 7.4. The RE 157 
response to changing pH was characterised in PBS at the same constant NaCl concentration, 158 
but with different pH values set by adjusting the ratio of monobasic to dibasic sodium 159 
phosphate. To characterise the RE response to chloride, aqueous NaCl was varied in 160 
concentration between 10 mM and 300 mM, while holding the total ionic strength constant at 161 
300 mM using NaNO3. On-chip RE potentials were measured relative to a commercial 162 
Ag|AgCl|KCl (3 M) reference electrode (Sigma-Aldrich). Linearity and sensitivity of the 163 
oxygen response were measured at atmospheric pressure in PBS that was bubbled with 164 
different mixtures of oxygen and nitrogen. The gas composition was set using a custom gas 165 
mixing rig that was manually adjusted to achieve specific dissolved oxygen concentrations, 166 
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which were directly measured in solution using a Seven2Go S9 meter with an InLab OptiOx 167 
probe (Mettler Toledo). Biofouling experiments were performed in air-saturated PBS 168 
containing 35 mg/mL BSA, and interference experiments were performed in air-saturated 169 
PBS containing either 3 µM hydrogen peroxide, 375 µM uric acid, 45 µM ascorbic acid, or 170 
100 µM paracetamol. 171 
 172 
2.6. Sensor sterilisation and irradiation 173 
 174 
Sensors were sterilised in ethylene oxide gas produced using an Anprolene AN-73 EtO gas 175 
ampoule (Andersen Products) at room temperature and pressure for 12 h, then left to degas 176 
for at least 2 h before use. For irradiation testing, sensors were immersed in 1.5 cm of PBS to 177 
provide a build-up region, and then exposed to a total radiotherapy dose of 24 Gy, delivered 178 
in four fractions of 6 Gy at 3 min intervals, under a 6 MV beam from a Varian Clinac 2100 179 
C/D linear accelerator (Varian Medical Systems). 180 
2.7. Lung tumour implantation 181 
Sheep studies were performed under a UK Home Office Project Licence in accordance with 182 
the Animals (Scientific Procedures) Act 1986 and approval from the University of Edinburgh 183 
Animal Welfare and Ethical Review Boards. Three adult female sheep (Highlander, n = 1; 184 
Scottish blackface, n = 2), weighing 52 - 65 kg and diagnosed with naturally occurring pre-185 
clinical ovine pulmonary adenocarcinoma, were obtained through an on-farm ultrasound 186 
eradication programme [36, 37]. Sheep were housed in groups of at least two animals, bedded 187 
on straw, with ad libitum access to food and water. Anaesthesia and analgesia were managed 188 
by a team of specialist veterinary anaesthetists. The clinical management and surgery of these 189 
cases has previously been described [38]. All animals received a central venous cannula 190 
placed in the jugular vein which was used for administering drugs and crystalloid fluids. An 191 
arterial cannula was also placed in the central auricular artery for monitoring arterial blood 192 
pressure and to obtain arterial blood samples. Intermittent blood-gas, biochemical, and 193 
haematological analysis was performed with an Epoc portable blood gas electrolyte and 194 
critical care analyser (Woodley Equipment Company). Pulse rate and blood pressure along 195 
with pulse oximetry, capnography, temperature, spirometry, electrocardiography and inspired 196 
and expired gases (O2, CO2, and inhalant anaesthetic agent) were continuously monitored 197 
using a Datex-Ohmeda S/5 multiparameter patient monitoring device (SOMA Technology). 198 
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All animals were euthanised with intravenous sodium pentobarbitone (Animalcare). CT 199 
imaging procedures were performed using a single-section SOMATOM Definition AS 64 200 
slice helical CT machine (Siemens Healthcare) [38]. 201 
All experiments were conducted on anaesthetised, non-recovery animals. Sensors were 202 
inserted using a trans-thoracic percutaneous technique under CT guidance using an 8G × 203 
15 cm Jamshidi biopsy needle (Carefusion). An initial CT scan was used to select an OPA 204 
lesion and plan the needle path trajectory for sensor implantation. Non-metallic, radiopaque 205 
grid lines (GuideLines, Oncology Imaging Systems) placed on the thoracic wall skin surface 206 
and intercostal spaces aided lesion localisation and determined the site for percutaneous 207 
sensor placement. Implantation was performed as previously described [38]. Briefly, a small 208 
skin incision was made approximately 1 – 2 intercostal spaces caudal to the desired entry 209 
point into the thoracic cavity through which the biopsy needle with its stylet in place was 210 
inserted. The needle was advanced cranially through subcutaneous tissues, then pushed 211 
through the chest wall at the desired intercostal space. A CT scan confirmed correct needle 212 
positioning before it was seated into the OPA tumour. Serial CT scans and needle 213 
advancements were made until the needle was positioned centrally within the tumour. Once 214 
positioned the stylet was removed, and a sterilised sensor and lead were introduced down the 215 
bore of the needle and pushed past the tip of the needle into OPA tissue. The implantation 216 
needle was withdrawn, leaving the sensor and lead wire in situ which was then sutured in 217 
place. A CT scan was performed to evaluate sensor positioning prior to testing, and a final 218 
scan was performed post-mortem to ensure the sensor had remained in place.  219 
To assess the ability of the implanted sensors to detect changes in intratumoral pO2 through 220 
changes in blood oxygenation, a series of alterations in target fraction of inspired oxygen 221 
(FiO2) was performed. The cycle of FiO2 alterations was: 1.00 (baseline), 0.50 (inducing mild 222 
hypoxaemia), 0.21 (inducing moderate hypoxaemia) before finally returning to 1.00. Each 223 
FiO2 step was performed for approximately 20 min (exact timings varied slightly according 224 
to clinical need, and are shown in Fig. S5). Arterial blood samples were taken at the end of 225 
each step. 226 
2.8. Statistical analysis 227 
Data were tested for normality using the Shapiro-Wilk test. Parametric testing on normally 228 
distributed data was performed using two-tailed paired t-tests to compare between two 229 
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groups, and a repeated measures one-way ANOVA followed by Dunnett’s post-hoc test to 230 
compare between three or more groups. For non-normally distributed data, a two-tailed 231 
Wilcoxon matched-pairs signed rank test was used to compare between two groups. Non-232 
linear regression with a semi-log line was used to fit the RE response to chloride 233 
concentration, and linear regression was used to fit the RE response to pH and the sensor 234 
response to oxygen partial pressure. Fitted parameters were compared to theoretical values 235 
using an extra sum-of-squares F-test. Statistical analysis was carried out using Prism 8 236 
(GraphPad). Values in the text and figures are presented as mean ± standard deviation (SD). 237 
3. Results  238 
3.1. Sensor fabrication 239 
Each sensor consists of a three-electrode electrochemical cell containing a 50 µm diameter 240 
circular WE, surrounded by a RE and CE with a WE:RE:CE area ratio of 1:3:10. The sensors 241 
were microfabricated on a silicon wafer, using conventional thin-film techniques to create 242 
platinum electrodes and external aluminium bond pads, followed by production of a Ag/AgCl 243 
layer on the RE by chemical oxidation of a thin-film of silver (Fig. 2a,b). Formation of AgCl 244 
was monitored using scanning electron microscopy with energy dispersive X-ray 245 
spectroscopy (SEM/EDX). X-ray peaks corresponding to silver were readily identified on the 246 
RE area prior to chloridisation, and additional elemental chlorine peaks corresponding to 247 
chloride were evident following chloridisation (Fig. 2c). Inspection of the surface using SEM 248 
showed that the initially smooth evaporated silver surface was modified by chloridisation, 249 
with granular structured AgCl growing on and into the electrode surface (Fig. 2d i-iii). The 250 
Ag/AgCl layer was also examined in cross-section using focussed ion beam milling followed 251 
by SEM. This showed a clearly visible layer of Ag/AgCl over the RE area, although there 252 
was no distinct division between the two materials, suggesting either a diffuse interfacial 253 
boundary or that little metallic silver remained (Fig. 2d iv). Separate investigation of the 254 
chloridisation process using a series of microfabricated silver thickness test structures 255 
confirmed that the latter was the case [39]. Since the Ag/AgCl layer was fabricated on an 256 
underlying layer of platinum, an electrically conductive path to the RE was maintained 257 
despite the highly efficient chloridisation. 258 
 259 
The Nafion membrane was then fabricated over the electrodes. To integrate this layer with 260 
subsequent wafer processing and packaging, we developed a novel series of processes in 261 
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which Nafion was spin-coated on the wafer, thermally annealed, patterned using 262 
photolithography and plasma etched at wafer level, and then temporarily protected using 263 
sacrificial layers of photoresist and Parylene-C (Fig. 2a and Fig. S1a,b). Fabricated sensor 264 
dies were wire bonded to a flexible printed circuit board (PCB) lead for connection to 265 
external instrumentation, and photocurable epoxy was used to selectively encapsulate the die 266 
edges, leaving an uncured window over the sensor active area (Fig. 2e,f) [40]. Finally, the 267 
protective layers were removed from the Nafion membrane prior to use (Fig. S1c). The final 268 
Nafion layer thickness was 518 ± 32 nm (n = 10 devices, from two wafers), measured by 269 
profilometry. 270 
 271 
3.2. Sensor characterisation 272 
 273 
Performance of the on-chip Ag/AgCl RE in packaged sensors was characterised in PBS 274 
against a commercial Ag/AgCl RE with an internal 3 M KCl filling solution. The median on-275 
chip RE potential was +74.0 mV (inter-quartile range: +71.7 to +76.4 mV, n = 81 sensors, 276 
from two wafers), confirming that the fabrication process had produced a functional and 277 
reproducible RE. We hypothesised that the small positive potential difference was due to the 278 
lower chloride activity in PBS contacting the on-chip RE compared to the concentrated KCl 279 
filling solution of the commercial RE, rather than a Donnan membrane potential [41]. To 280 
confirm this, the concentration of sodium chloride in solution bathing the sensor was varied 281 
while holding the ionic strength constant using sodium nitrate to maintain constant activity. 282 
The on-chip RE potential changed with the logarithm of chloride concentration, giving a 283 
slope of −58.6 mV/dec (Fig. S2a). This was not significantly different to an ideal Nernstian 284 
response of −58.2 mV/dec, supporting the hypothesis. The response of the RE to changing 285 
pH was also evaluated in PBS over a physiological range of pH 6.2 – 7.8, and showed no 286 
significant variation, as expected (Fig. S2b). 287 
To establish whether the Nafion layer was acting as a protective sensor membrane in the 288 
packaged sensors, we performed cyclic voltammetry (CV) at the WE in a solution of 289 
potassium ferricyanide and potassium ferrocyanide. The ferri/ferrocyanide anions should be 290 
excluded from Nafion (due to their size and/or charge), and thus blocked from reacting at the 291 
WE. Consistent with this, no redox processes were visible in the cyclic voltammograms from 292 
Nafion coated sensors. In contrast, control devices lacking a Nafion membrane showed clear 293 
peaks corresponding to the reduction and oxidation of the ferro/ferricyanide in solution, 294 
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indicating their presence at the electrode surface (Fig. 3a). These results show that the 295 
fabricated Nafion membrane fully covered the WE surface and that no defects were 296 
introduced into the layer during packaging. In addition, they confirm that the epoxy 297 
packaging was effective at hermetically sealing the bond pads and wire bonds from contact 298 
with external solutions. 299 
To characterise the electrochemical performance of the complete sensor system we 300 
performed CV in PBS using the on-chip WE, RE and CE. The WE potential was swept 301 
between −0.7 V and +0.9 V (vs the on-chip Ag/AgCl RE), remaining within the 302 
electrochemical potential window of the system. An initial slight peak then pronounced wave 303 
at approximately −0.5 V was visible, and was absent after purging oxygen from the PBS 304 
solution using nitrogen (Fig. 3b). This indicates that the peak was caused by oxygen 305 
reduction at the WE surface, and the wave by diffusion limited oxygen reduction through the 306 
Nafion membrane. These results confirmed that the annealed Nafion membrane was capable 307 
of permitting oxygen and small ion transport. Additional peaks were frequently evident in the 308 
PBS CV at approximately +0.07 V and −0.15 V, which are characteristic of silver chloride 309 
and may indicate some mechanical transfer from the RE onto the WE surface during 310 
fabrication. However, these were well separated in potential from the oxygen reduction 311 
reaction, and were not observed to interfere with its position or magnitude. 312 
We next performed chronoamperometry (CA) at −0.5 V (vs the on-chip Ag/AgCl RE) for 313 
20 s. In air-saturated PBS the WE current showed an expected initial transient related to 314 
capacitive charging, reduction of oxygen, and formation of oxygen diffusion gradients at its 315 
surface (consistent with the CV peak). This was followed by the development of an 316 
approximately steady-state current caused by diffusion-controlled oxygen reduction 317 
(consistent with the CV wave). In nitrogen purged PBS the steady-state current was markedly 318 
decreased, again consistent with the CV results and identifying the current as oxygen 319 
reduction (Fig. 3c). To investigate the linearity of the oxygen response, its partial pressure 320 
(pO2) in solution was varied from 0.1 to 25.3 kPa (equivalent to 0.1 to 25.0% of atmospheric 321 
pressure) by sparging with a range of oxygen/nitrogen mixtures. A greater sampling 322 
resolution was used in the lower range relevant to biological tissue. The sensor response to 323 
oxygen was quantified using the mean current over the final 5 s of a 20 s CA recording, as 324 
the steady-state was well established by this point. Linear regression showed a proportional 325 
relationship between the steady-state current and oxygen concentration (r2 = 0.991), with a 326 
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fitted sensitivity of −0.595 ± 0.009 nA/kPa and a statistically insignificant offset of −0.143 ± 327 
0.100 nA (Fig. 3d). Quantification of oxygen concentration as the mean steady-state CA 328 
current at −0.5 V (vs on-chip Ag/AgCl RE), averaged over the final 5 s of a 20 s recording, 329 
was therefore adopted for all further measurements. Together these results show that the 330 
sensor output varies directly with oxygen concentration as expected, with insignificant offset 331 
due to unrelated currents at the WE. 332 
To investigate the performance of the packaged sensors over time, oxygen measurements 333 
using CA were repeatedly performed in air-saturated PBS. The RE potential was also 334 
recorded from the same devices against an external Ag/AgCl RE in the rest periods between 335 
CA measurements. Over 4 h the sensors gave an average steady-state current of 336 
−11.4 ± 0.8 nA (n = 8 sensors) in air-saturated PBS (Fig. 3e). To quantify individual sensor 337 
stability, the coefficient of variance (CoV, defined as [SD / Mean] × 100%) of the output 338 
from each sensor was also calculated, and gave a mean CoV of 12.2% over the 4 h 339 
measurement period (n = 8 sensors). The RE potential remained very stable over the same 340 
period (Fig. 3f), with an average value of +74.8 ± 1.5 mV (n = 8 sensors), and a mean CoV of 341 
only 0.33% (n = 8 sensors). The measurements were then continued until sensor failure to 342 
investigate their lifetime. Ultimately the first element of the sensor to fail was the RE. A 343 
change in RE potential typically occurred quite suddenly, leading in turn to unreliable CA 344 
oxygen measurements as the WE bias could not be accurately set (Fig. S3). A difference in 345 
RE potential of more than ±50 mV from its initial value was defined as the failure point, and 346 
gave a mean time-to-failure of 23.3 h (range 5.1 – 64.5 h, n = 8 sensors). 347 
We next systematically explored how sensor performance may be affected by exposure to the 348 
in vivo environment. To test whether the sensor was susceptible to protein biofouling, we 349 
recorded oxygen measurements from sensors in air-saturated PBS containing bovine serum 350 
albumin (BSA). This is a well characterised, water soluble protein, commonly used as a 351 
surrogate to model biofouling. Air-saturated PBS alone was used as a control. Sensors 352 
exposed to BSA showed a significant decrease in steady-state WE current after 24 h (Fig. 4a), 353 
suggesting that biofouling due to non-specific protein adsorption may lower the sensitivity of 354 
the Nafion coated sensors. We then tested the interference effect of common electroactive 355 
compounds (hydrogen peroxide, urate, ascorbate, and paracetamol) that are found in vivo and 356 
known to affect electrochemical measurements. Compounds were dissolved in air-saturated 357 
PBS, and oxygen measurements were sequentially performed in each solution in a 358 
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randomised order. When compared to PBS alone, we found that physiological concentrations 359 
of hydrogen peroxide (3 µM), ascorbate (45 µM), and paracetamol (100 µM) all had no 360 
significant effect on the steady-state WE current, while urate (375 µM) caused a significant 361 
decrease in the magnitude of the current (Fig. 4b). 362 
As the sensor was designed to be surgically implanted and remain in place during a course of 363 
radiotherapy, we finally tested whether it was adversely affected by sterilisation or 364 
irradiation. Ethylene oxide gas was used to sterilise the sensors as it is routinely used to 365 
sterilise medical equipment. Irradiation was performed under a clinical radiotherapy beam, 366 
using a dose of four fractions of 6 Gy. This fraction size is within the upper range typically 367 
delivered in human clinical use [42], and matches that used in previous work involving a 368 
sheep lung cancer model [43]. Following these treatments, the on-chip RE potential was 369 
unchanged (Fig. 5a), and the Nafion membrane was still impermeable to ferri/ferrocyanide 370 
anions (Fig. 5b), indicating that its physical integrity and selectivity had not been 371 
compromised. Using CV in PBS we observed that the expected oxygen reduction features 372 
were still evident (Fig. 5c), and that the corresponding CA steady-state oxygen current at 373 
−0.5 V (vs the on-chip Ag/AgCl RE) was also unchanged (Fig. 5d), showing that the 374 
electrodes were undamaged. 375 
3.3. In vivo validation 376 
Bench characterisation showed that the sensor could report oxygen concentration in solution 377 
effectively over many hours. We therefore next tested whether the sensor was sufficiently 378 
robust to operate in vivo and detect dynamic changes in tissue oxygenation. We used a novel 379 
clinically relevant ovine model of lung cancer [38], developed specifically for this project. 380 
Tumours in three sheep with naturally occurring pre-clinical ovine pulmonary 381 
adenocarcinoma were implanted with either one sensor (Cases F1 & F2) or two sensors (Case 382 
F3). Each sensor was implanted under anaesthesia using a Jamshidi needle using CT 383 
guidance (Fig. 6a,b). The sheep were initially maintained at a target FiO2 of 1.00, then 384 
exposed to a protocol of mild graded tissue hypoxia by stepping their FiO2 down to 0.50 and 385 
then 0.21, before being returned to an FiO2 of 1.00 (Fig. 6c). Arterial blood analysis showed 386 
the expected changes in oxygenation (Fig. 6d and Fig. S4a), while other relevant 387 
physiological variables did not change significantly (Fig. S4b-e). During the protocol, 388 
measurements were repeatedly made from the sensors using CA and all gave measurable 389 
real-time outputs (Fig. S5). Interestingly, there was substantial variability between cases and 390 
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so readings from each sensor were analysed independently. Both sensors in Case F3 showed 391 
low initial currents which did not respond to changes in FiO2, while the sensors in Cases F1 392 
and F2 showed a relatively higher initial current with partially reversible decreases at lower 393 
FiO2 values and a decrease following euthanasia (Fig. 6e). These differences reflect the 394 
expected heterogeneity of tumour hypoxia and oxygen responsiveness. 395 
To confirm that the sensors survived the tumour implantation procedure they were recovered 396 
following euthanasia, gently rinsed in water, and tested. Their surfaces showed the presence 397 
of some contamination (Fig. 7a), likely derived from lung tissue at the implant site. CV in air-398 
saturated PBS showed the expected presence of oxygen reduction at negative potentials for 399 
all sensors (Fig. 7b). The mean steady-state CA current showed greater variability between 400 
sensors post-implantation but was not significantly different to its pre-implantation value 401 
(Fig. 7c). Together these results demonstrate that the packaged sensor is sufficiently 402 
physically robust to remain functional throughout a clinically realistic implantation 403 
procedure. 404 
4. Discussion  405 
Together, this work describes a microfabricated electrochemical oxygen sensor that is 406 
suitable for implantation, and demonstrates its functionality and relevance for real-time 407 
measurement in a realistic clinical environment. The wafer-level microfabrication approach 408 
we adopted for producing the sensor has two advantages. Firstly, it enables the sensor to be 409 
mass manufacturable with high repeatability through use of standard industrial tools and tight 410 
process control, and minimises costly and potentially inconsistent die-level processing. These 411 
features will be very important for gaining medical regulatory approval, as sensor accuracy 412 
and repeatability are essential for making safe clinical decisions. Secondly, it will enable our 413 
future aim of post-processing the oxygen sensor architecture on CMOS wafers to produce a 414 
device that contains integrated potentiostat instrumentation and wireless power and 415 
communication electronics. This will also allow the volume of the device to be minimised by 416 
eliminating dependence on the existing assembly and packaging elements required for 417 
connection to external instrumentation. 418 
The sensor membrane is a defining component of the Clark electrode, separating its bare 419 
electrodes from the chemically complex surrounding fluid. Our membrane was fabricated 420 
from Nafion, a perfluorinated cation exchange resin that is both oxygen permeable and can 421 
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conduct protons between electrodes to support the electrochemical reactions [17]. Wafer-422 
level spin coating was used to deposit the Nafion membrane, followed by heat annealing. 423 
Annealing increases Nafion solvent resistance [44], improving integration with standard wet 424 
microfabrication processes and improving its stability in aqueous environments. Furthermore, 425 
it also improves Nafion proton conductivity and electrochemical surface area [45, 46], tensile 426 
strength [45], and the lifetime of implanted Nafion coated Ag/AgCl reference electrodes [35]. 427 
Photolithographic patterning and dry etching were then used to accurately define the 428 
membrane areas across the wafer. Together this novel combination of processes significantly 429 
improved manufacturability compared to previously described microfabricated oxygen 430 
sensors that used die-level drop cast Nafion membranes that were not annealed [21, 23, 28]. 431 
Selectivity of the Clark sensor membrane is important for sensor accuracy. The polymer 432 
backbone of Nafion carries negatively charged sulphonate groups that can electrostatically 433 
exclude anionic species, and the nanometer scale of its hydrophillic pores causes size 434 
exclusion of large ions [17]. Consistent with these effects, we observed that our membrane 435 
blocked ferricyanide ([Fe(CN)6]3−) and ferrocynanide ([Fe(CN)6]4−) ions from reacting at the 436 
WE. In addition, no significant interference was observed from physiological concentrations 437 
of ascorbate, hydrogen peroxide, or paracetamol. We found that urate decreased the measured 438 
current from the sensor, indicating that it may interfere with oxygen measurements. There is 439 
conflicting literature regarding Nafion permeability to urate, with several reports showing 440 
that Nafion improves selectivity for catecholamine neurotransmitter measurements in the 441 
presence of urate [47], while others have shown that it can be used to block ascorbate and 442 
allow selective measurement of urate [48-50]. Our data suggest that the Nafion sensor 443 
membrane is permeable to urate, likely in its protonated uric acid form as it would otherwise 444 
be electrostatically excluded, and may become deposited within the hydrated pores limiting 445 
mass transport. 446 
An additional function of the membrane was to prevent electrode biofouling. Nafion is 447 
generally thought to reduce biofouling [33, 34], however we observed that exposure of the 448 
sensor to a solution of BSA caused a significant decrease in its oxygen sensitivity over 24 h. 449 
This is likely to be due to surface adsorption of protein, since BSA will be size excluded from 450 
the Nafion membrane pores. Biofouling may partly account for the measured variability in 451 
the performance of sensors that were recovered at post-mortem following tumour 452 
implantation, and it will need to be addressed before translation to human clinical trials. 453 
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An essential component of any electrochemical sensor is the RE, necessary to provide the 454 
potential against which the WE potential is measured or set. Key parameters of RE 455 
performance are potential stability, sensitivity to environmental variables, and lifetime. Our 456 
Nafion coated Ag/AgCl RE successfully provided a sufficiently stable potential to enable 457 
accurate measurements to be made both in vitro and in vivo. Its potential was set by the 458 
surrounding chloride concentration in a typical Nerstian response, as others have previously 459 
observed for reference electrodes without a defined internal electrolyte [16]. This is not 460 
expected to cause problems in an implanted setting, as chloride concentration is under tight 461 
homeostatic control, with a typical range of 97 – 107 mM in human plasma [51]. During 462 
long-term testing, we typically saw failure (defined by a sudden large potential change) of the 463 
RE in less than a day, leading to unreliable measurements. This may reflect mechanical 464 
instability of the AgCl layer, or exhaustion of either Ag or AgCl. The failure origin will be 465 
investigated, since the short lifetime of our sensor remains a limitation that will need to be 466 
improved for clinical applications. 467 
The sensor was designed from the start for implantation, and so all the outward facing 468 
materials were selected for their established biocompatibility, including silicon dioxide [52-469 
54], Nafion [55-57], and Epotek OG116-31 epoxy resin. We have recently demonstrated that 470 
implantation of these sensor materials does not cause changes in tumour pathology [58], 471 
which will be essential for clinical deployment. Others have previously shown that a large 472 
implanted Ag/AgCl RE can cause local toxicity. To minimise this risk, we used a Nafion RE 473 
coating which is known to reduce the toxicity of implanted Ag/AgCl electrodes [35]. The 474 
PCB insulation was manufactured from polyimide, which is already commonly used for 475 
encapsulating and insulating implantable medical devices [59]. 476 
To validate the sensor in tumour tissue we used an ovine pulmonary adenocarcinoma model. 477 
This model has high translational value, as it closely reflects both human lung cancer biology 478 
[60], and the surgical methods used for tumour management such as trans-thoracic needle 479 
biopsy [38]. The experiments described here represents the first use of this novel preclinical 480 
model for validation of an implantable sensor in tumour tissue. Oxygen sensor readings 481 
obtained from the implanted sensors showed substantial variation between cases, consistent 482 
with a poorly perfused hypoxic tumour environment at both sensor locations in Case F3, but 483 
better perfusion and responsiveness to changes in blood oxygenation at the sensor locations 484 
in Cases F1 and F2. This underlines the known spatial heterogeneity of hypoxia that is found 485 
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in solid tumours [1]. Interestingly, our results are also consistent with a previous human lung 486 
cancer study which showed highly variable responsiveness of tumour hypoxia to breathing 487 
95% oxygen as a potential radiotherapy sensitising technique [61]. 488 
Hypoxia is also a feature of many other pathological states. These include chronic conditions 489 
such as non-healing wounds [62], while acute disruption occurs in life-threatening conditions 490 
such as hypovolaemic, cardiogenic and septic shock [63], and following traumatic brain 491 
injury [64]. Our minimally invasive technique for continuously measuring tissue oxygenation 492 
could therefore also be a valuable tool for clinicians involved in the treatment and 493 
management of a broad range of other medical conditions. We are currently engaged in 494 
further implantation studies to determine whether the sensor is suitable for post-surgical 495 
monitoring of intestinal tissue oxygenation following resection and anastomosis [65]. 496 
 497 
5. Conclusion 498 
Hypoxia is distributed heterogeneously within solid tumours, and can vary over time. It 499 
inhibits the effectiveness of radiotherapy treatment, arguing for tumour oxygenation status to 500 
be included in radiotherapy planning. Here, we describe a miniature implantable sensor for 501 
continuous real-time monitoring of tumour hypoxia. The fabrication process comprises only 502 
CMOS compatible wafer-level processing techniques, and produces a novel layer stack 503 
suitable for integration with biocompatible epoxy encapsulation. The sensor gave a linear 504 
response to oxygen, although it showed some susceptibility to biofouling and interference by 505 
urate, and its lifetime was limited to between hours and days by failure of the on-chip RE. 506 
We showed that the packaged sensor was sufficiently robust to function over this timescale 507 
within a tumour using a translational model of lung cancer, and demonstrated measurement 508 
of dynamic changes in tissue oxygenation in vivo. Our future work will focus on addressing 509 
the limitations of sensor lifetime and selectivity, alleviating the effects of biofouling, and 510 
ultimately achieving full integration with on-chip instrumentation and wireless power and 511 
communications.   512 
Page 19 of 36 
Acknowledgements  513 
This work was supported by funding from the UK Engineering and Physical Sciences 514 
Research Council through the Implantable Microsystems for Personalised Anti-Cancer 515 
Therapy (IMPACT) programme grant (EP/K034510/1), from a project grant from Bowel and 516 
Cancer Research UK, and from a Wellcome Trust Biomedical Resource Grant to the 517 
Wellcome Trust Critical Care Laboratory for Large Animals (104972/Z/14/Z). We are 518 
grateful to S. Ramsay and R. Blair for their technical assistance during sensor fabrication, E. 519 
MacDonald for constructing the O2/N2 gas mixing apparatus used for sensor characterisation, 520 
I. Schmueser for advice on electrochemistry, E. Kay and H. Porter for assistance and advice 521 
during sensor irradiation testing, J. Nixon, P. Tennant and A. Ritchie for sheep husbandry and 522 
sensor sterilisation, and L. Grant for CT imaging. Sheep OPA cases were obtained by P. Scott 523 
(Capital Veterinary Services). 524 
Author contributions  525 
AFM, DJA, AJW, ARM & IHK conceived the approach. CD, JRKM, EOB, AT & EG-F 526 
designed and fabricated the sensors. JRKM, CD, EOB & MEG performed the sensor 527 
characterisation experiments. MMP performed the sensor irradiation. MEG, AD, MS & MAP 528 
developed methodology for in vivo recording. MEG, PS, SNG, RG, REC & DJA developed 529 
methodology for the lung tumour implantation experiments and performed the sheep in vivo 530 
work. JRKM & ARM analysed the data. AFM, DJA, AJW, IU, ARM, SS, JGT, SM, MAP, 531 
MS & REC supervised the experiments. JRKM & MEG wrote the manuscript, and it was 532 
reviewed and edited by all the authors. 533 
Competing interests 534 
The authors declare no competing interests.  535 
Page 20 of 36 
References 536 
[1] M. Hockel and P. Vaupel, "Tumor Hypoxia: Definitions and Current Clinical, 537 
Biologic, and Molecular Aspects," JNCI Journal of the National Cancer Institute, vol. 538 
93, no. 4, pp. 266-276, 2001, doi: 10.1093/jnci/93.4.266. 539 
[2] M. W. Dewhirst, Y. Cao, and B. Moeller, "Cycling hypoxia and free radicals regulate 540 
angiogenesis and radiotherapy response," Nature Reviews Cancer, vol. 8, no. 6, pp. 541 
425-437, 2008, doi: 10.1038/nrc2397. 542 
[3] L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. C. A. Scott, "The 543 
Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor 544 
in Radiotherapy," The British Journal of Radiology, vol. 26, no. 312, pp. 638-648, 545 
1953, doi: 10.1259/0007-1285-26-312-638. 546 
[4] P. Vaupel and A. Mayer, "Hypoxia in cancer: significance and impact on clinical 547 
outcome," Cancer Metastasis Rev, vol. 26, no. 2, pp. 225-39, 2007, doi: 548 
10.1007/s10555-007-9055-1. 549 
[5] S. M. Bentzen and V. Gregoire, "Molecular Imaging–Based Dose Painting: A Novel 550 
Paradigm for Radiation Therapy Prescription," Seminars in Radiation Oncology, vol. 551 
21, no. 2, pp. 101-110, 2011, doi: 10.1016/j.semradonc.2010.10.001. 552 
[6] S. A. Bhide and C. M. Nutting, "Recent advances in radiotherapy," BMC Medicine, 553 
vol. 8, no. 1, p. 25, 2010, doi: 10.1186/1741-7015-8-25. 554 
[7] E. M. Hammond, M. C. Asselin, D. Forster, J. P. O'Connor, J. M. Senra, and K. J. 555 
Williams, "The meaning, measurement and modification of hypoxia in the laboratory 556 
and the clinic," Clinical Oncology, vol. 26, no. 5, pp. 277-88, 2014, doi: 557 
10.1016/j.clon.2014.02.002. 558 
[8] B. Epel, M. Kotecha, and H. J. Halpern, "In vivo preclinical cancer and tissue 559 
engineering applications of absolute oxygen imaging using pulse EPR," Journal of 560 
Magnetic Resonance, vol. 280, pp. 149-157, 2017, doi: 10.1016/j.jmr.2017.04.017. 561 
[9] P. Vaupel, M. Höckel, and A. Mayer, "Detection and Characterization of Tumor 562 
Hypoxia Using pO2 Histography," Antioxidants & Redox Signaling, vol. 9, no. 8, pp. 563 
1221-1236, 2007, doi: 10.1089/ars.2007.1628. 564 
[10] J. R. K. Marland et al., "Implantable Microsystems for Personalised Anticancer 565 
Therapy," CMOS Circuits for Biological Sensing and Processing, pp. 259-286, 2018, 566 
doi: 10.1007/978-3-319-67723-1_11. 567 
[11] T. Ikegwuonu, G. Haddow, J. Tait, A. F. Murray, and I. H. Kunkler, "Horizon 568 
scanning implanted biosensors in personalising breast cancer management: First pilot 569 
study of breast cancer patients views," Health Science Reports, vol. 1, no. 4, p. e30, 570 
2018, doi: 10.1002/hsr2.30. 571 
[12] H. L. Danneel, "Über den durch Diffundierende Gase Hervorgerufenen Reststrom," 572 
Zeitschrift für Elektrochemie, vol. 4, no. 9, pp. 227-242, 1897, doi: 573 
doi:10.1002/bbpc.18970040903. 574 
[13] L. C. Clark, "Monitor and control of blood and tissue oxygen tension," Transactions - 575 
American Society for Artificial Internal Organs, vol. 2, pp. 41-48, 1956. 576 
[14] A. M. Gómez–Marín and E. A. Ticianelli, "A reviewed vision of the oxygen reduction 577 
reaction mechanism on Pt-based catalysts," Current Opinion in Electrochemistry, vol. 578 
9, pp. 129-136, 2018, doi: 10.1016/j.coelec.2018.03.008. 579 
[15] J. W. Severinghaus and P. B. Astrup, "History of blood gas analysis. IV. Leland 580 
Clark's oxygen electrode," Journal of Clinical Monitoring, vol. 2, no. 2, pp. 125-139, 581 
1986, doi: 10.1007/bf01637680. 582 
[16] M. W. Shinwari, D. Zhitomirsky, I. A. Deen, P. R. Selvaganapathy, M. J. Deen, and 583 
D. Landheer, "Microfabricated Reference Electrodes and their Biosensing 584 
Page 21 of 36 
Applications," Sensors, vol. 10, no. 3, pp. 1679-1715, 2010, doi: 585 
10.3390/s100301679. 586 
[17] A. Kusoglu and A. Z. Weber, "New Insights into Perfluorinated Sulfonic-Acid 587 
lonomers," Chem Rev, vol. 117, no. 3, pp. 987-1104, 2017, doi: 588 
10.1021/acs.chemrev.6b00159. 589 
[18] T. Xiao et al., "In Vivo Monitoring of Oxygen Fluctuation Simultaneously at Multiple 590 
Sites of Rat Cortex during Spreading Depression," Analytical Chemistry, vol. 90, no. 591 
22, pp. 13783-13789, 2018, doi: 10.1021/acs.analchem.8b04348. 592 
[19] J. Kieninger et al., "Sensor Access to the Cellular Microenvironment Using the 593 
Sensing Cell Culture Flask," Biosensors (Basel), vol. 8, no. 2, pp. 1-11, 2018, doi: 594 
10.3390/bios8020044. 595 
[20] S. M. Bonk et al., "Design and Characterization of a Sensorized Microfluidic Cell-596 
Culture System with Electro-Thermal Micro-Pumps and Sensors for Cell Adhesion, 597 
Oxygen, and pH on a Glass Chip," Biosensors (Basel), vol. 5, no. 3, pp. 513-536, 598 
2015, doi: 10.3390/bios5030513. 599 
[21] W. P. Chan et al., "A Monolithically Integrated Pressure/Oxygen/Temperature 600 
Sensing SoC for Multimodality Intracranial Neuromonitoring," Ieee J Solid-St Circ, 601 
vol. 49, no. 11, pp. 2449-2461, 2014, doi: 10.1109/Jssc.2014.2345754. 602 
[22] Y. Eminaga, M. Brischwein, J. Wiest, J. Clauss, S. Becker, and B. Wolf, "Self 603 
calibration of a planar dissolved oxygen sensor," Sensors and Actuators B: Chemical, 604 
vol. 177, pp. 785-791, 2013, doi: 10.1016/j.snb.2012.11.104. 605 
[23] P. Wang, Y. Liu, H. D. Abruna, J. A. Spector, and W. L. Olbricht, "Micromachined 606 
dissolved oxygen sensor based on solid polymer electrolyte," Sensor Actuat B-Chem, 607 
vol. 153, no. 1, pp. 145-151, 2011, doi: 10.1016/j.snb.2010.09.075. 608 
[24] C. C. Wu, H. N. Luk, Y. T. T. Lin, and C. Y. Yuan, "A Clark-type oxygen chip for in 609 
situ estimation of the respiratory activity of adhering cells," Talanta, vol. 81, no. 1-2, 610 
pp. 228-234, 2010, doi: 10.1016/j.talanta.2009.11.062. 611 
[25] J. Park, Y. K. Pak, and J. J. Pak, "A microfabricated reservoir-type oxygen sensor for 612 
measuring the real-time cellular oxygen consumption rate at various conditions," 613 
Sensors and Actuators B: Chemical, vol. 147, no. 1, pp. 263-269, 2010, doi: 614 
10.1016/j.snb.2010.03.069. 615 
[26] C. C. Wu, T. Yasukawa, H. Shiku, and T. Matsue, "Fabrication of miniature Clark 616 
oxygen sensor integrated with microstructure," Sensor Actuat B-Chem, vol. 110, no. 617 
2, pp. 342-349, 2005, doi: 10.1016/j.snb.2005.02.014. 618 
[27] M. Brischwein, E. R. Motrescu, E. Cabala, A. M. Otto, H. Grothe, and B. Wolf, 619 
"Functional cellular assays with multiparametric silicon sensor chips," Lab Chip, vol. 620 
3, no. 4, pp. 234-240, 2003, doi: 10.1039/b308888j. 621 
[28] G. W. McLaughlin, K. Braden, B. Franc, and G. T. A. Kovacs, "Microfabricated 622 
solid-state dissolved oxygen sensor," Sensor Actuat B-Chem, vol. 83, no. 1-3, pp. 623 
138-148, 2002, doi: 10.1016/S0925-4005(02)00021-7. 624 
[29] H. Suzuki, T. Hirakawa, S. Sasaki, and I. Karube, "An integrated module for sensing 625 
pO2, pCO2, and pH," Anal Chim Acta, vol. 405, no. 1-2, pp. 57-65, 2000, doi: Doi 626 
10.1016/S0003-2670(99)00748-5. 627 
[30] H. X. Zhu, T. C. Lo, R. Lenigk, and R. Renneberg, "Fabrication of a novel oxygen 628 
sensor with CMOS compatible processes," Sensors and Actuators B: Chemical, vol. 629 
46, no. 2, pp. 155-159, 1998, doi: 10.1016/S0925-4005(98)00044-6. 630 
[31] H. Yin, X. Mu, H. Li, X. Liu, and A. J. Mason, "CMOS Monolithic Electrochemical 631 
Gas Sensor Microsystem Using Room Temperature Ionic Liquid," Ieee Sens J, vol. 632 
18, no. 19, pp. 7899-7906, 2018, doi: 10.1109/jsen.2018.2863644. 633 
Page 22 of 36 
[32] J. R. K. Marland et al., "Optimization of Nafion Polymer Electrolyte Membrane 634 
Design and Microfabrication," IEEE Transactions on Semiconductor Manufacturing, 635 
pp. 1-1, 2020, doi: 10.1109/tsm.2020.2983875. 636 
[33] G. Rocchitta et al., "Enzyme Biosensors for Biomedical Applications: Strategies for 637 
Safeguarding Analytical Performances in Biological Fluids," Sensors, vol. 16, no. 6, 638 
p. 780, 2016, doi: 10.3390/s16060780. 639 
[34] N. Wisniewski and M. Reichert, "Methods for reducing biosensor membrane 640 
biofouling," Colloid Surface B, vol. 18, no. 3-4, pp. 197-219, 2000, doi: 641 
10.1016/S0927-7765(99)00148-4. 642 
[35] F. Moussy and D. J. Harrison, "Prevention of the Rapid Degradation of 643 
Subcutaneously Implanted Ag/Agcl Reference Electrodes Using Polymer-Coatings," 644 
Analytical Chemistry, vol. 66, no. 5, pp. 674-679, 1994, doi: 10.1021/ac00077a015. 645 
[36] P. R. Scott, M. P. Dagleish, and C. Cousens, "Development of superficial lung lesions 646 
monitored on farm by serial ultrasonographic examination in sheep with lesions 647 
confirmed as ovine pulmonary adenocarcinoma at necropsy," Irish Veterinary 648 
Journal, vol. 71, no. 1, p. 23, 2018, doi: 10.1186/s13620-018-0134-0. 649 
[37] C. Cousens and P. R. Scott, "Assessment of transthoracic ultrasound diagnosis of 650 
ovine pulmonary adenocarcinoma in adult sheep," Veterinary Record, vol. 177, no. 651 
14, pp. 366-366, 2015, doi: 10.1136/vr.103298. 652 
[38] M. E. Gray et al., "A Novel Translational Ovine Pulmonary Adenocarcinoma Model 653 
for Human Lung Cancer," Frontiers in Oncology, vol. 9, p. 534, 2019, doi: 654 
10.3389/fonc.2019.00534. 655 
[39] C. Dunare et al., "Test Structures for Characterising the Silver Chlorination Process 656 
During Integrated Ag/AgCl Reference Electrode Fabrication," 2019 International 657 
Conference of Microelectronic Test Structures (ICMTS), 2019, doi: 658 
10.1109/ICMTS.2019.8730966. 659 
[40] E. O. Blair et al., "Test structures for the characterisation of sensor packaging 660 
technology," 2017 International Conference of Microelectronic Test Structures 661 
(ICMTS), pp. 1-6, 2017, doi: 10.1109/icmts.2017.7954279. 662 
[41] T. Luo, S. Abdu, and M. Wessling, "Selectivity of ion exchange membranes: A 663 
review," Journal of Membrane Science, vol. 555, pp. 429-454, 2018, doi: 664 
10.1016/j.memsci.2018.03.051. 665 
[42] M. V. Williams, N. D. James, E. T. Summers, A. Barrett, and D. V. Ash, "National 666 
Survey of Radiotherapy Fractionation Practice in 2003," Clinical Oncology, vol. 18, 667 
no. 1, pp. 3-14, 2006, doi: 10.1016/j.clon.2005.10.002. 668 
[43] D. Collie et al., "Nebulisation of synthetic lamellar lipids mitigates radiation-induced 669 
lung injury in a large animal model," Scientific Reports, vol. 8, no. 1, p. 13316, 2018, 670 
doi: 10.1038/s41598-018-31559-3. 671 
[44] L. A. Zook and J. Leddy, "Density and solubility of nafion: Recast, annealed, and 672 
commercial films," Analytical Chemistry, vol. 68, no. 21, pp. 3793-3796, 1996, doi: 673 
10.1021/ac960604e. 674 
[45] X. Y. Ding, S. Didari, T. F. Fuller, and T. A. L. Harris, "Effects of Annealing 675 
Conditions on the Performance of Solution Cast Nafion Membranes in Fuel Cells," J 676 
Electrochem Soc, vol. 160, no. 8, pp. F793-F797, 2013, doi: 10.1149/2.034308jes. 677 
[46] H. Y. Jung, K. Y. Cho, Y. M. Lee, J. K. Park, J. H. Choi, and Y. E. Sung, "Influence 678 
of annealing of membrane electrode assembly (MEA) on performance of direct 679 
methanol fuel cell (DMFC)," J Power Sources, vol. 163, no. 2, pp. 952-956, 2007, 680 
doi: 10.1016/j.jpowsour.2006.09.047. 681 
Page 23 of 36 
[47] J. A. Ribeiro, P. M. V. Fernandes, C. M. Pereira, and F. Silva, "Electrochemical 682 
sensors and biosensors for determination of catecholamine neurotransmitters: A 683 
review," Talanta, vol. 160, pp. 653-679, 2016, doi: 10.1016/j.talanta.2016.06.066. 684 
[48] Z. Xu et al., "Non-enzymatic electrochemical detection of uric acid with 685 
electrodeposited Nafion film," Journal of Electroanalytical Chemistry, vol. 841, pp. 686 
129-134, 2019, doi: 10.1016/j.jelechem.2019.04.028. 687 
[49] B. Yan et al., "Glassy carbon electrode modified with G‑MoS2‑Nafion acts as an 688 
electrochemical biosensor to determine uric acid in human serum," Molecular 689 
Medicine Reports, 2018, doi: 10.3892/mmr.2018.9314. 690 
[50] Y.-K. Chih and M.-C. Yang, "An 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic 691 
acid)-immobilized electrode for the simultaneous detection of dopamine and uric acid 692 
in the presence of ascorbic acid," Bioelectrochemistry, vol. 91, pp. 44-51, 2013, doi: 693 
10.1016/j.bioelechem.2013.01.001. 694 
[51] K. Berend, L. H. van Hulsteijn, and R. O. B. Gans, "Chloride: The queen of 695 
electrolytes?," European Journal of Internal Medicine, vol. 23, no. 3, pp. 203-211, 696 
2012, doi: 10.1016/j.ejim.2011.11.013. 697 
[52] G. Voskerician et al., "Biocompatibility and biofouling of MEMS drug delivery 698 
devices," Biomaterials, vol. 24, no. 11, pp. 1959-1967, 2003, doi: 10.1016/s0142-699 
9612(02)00565-3. 700 
[53] G. Kotzar et al., "Evaluation of MEMS materials of construction for implantable 701 
medical devices," Biomaterials, vol. 23, no. 13, pp. 2737-2750, 2002, doi: 702 
10.1016/s0142-9612(02)00007-8. 703 
[54] S. S. Stensaas and L. J. Stensaas, "Histopathological evaluation of materials 704 
implanted in the cerebral cortex," Acta Neuropathologica, vol. 41, no. 2, pp. 145-155, 705 
1978, doi: 10.1007/bf00689766. 706 
[55] Y. J. Lee, H.-J. Kim, J. Y. Kang, S. H. Do, and S. H. Lee, "Biofunctionalization of 707 
Nerve Interface via Biocompatible Polymer-Roughened Pt Black on Cuff Electrode 708 
for Chronic Recording," Advanced Healthcare Materials, vol. 6, no. 6, pp. 1-12, 709 
2017, doi: 10.1002/adhm.201601022. 710 
[56] G. Kim, H. Kim, I. J. Kim, J. R. Kim, J. I. Lee, and M. Ree, "Bacterial Adhesion, Cell 711 
Adhesion and Biocompatibility of Nafion Films," Journal of Biomaterials Science, 712 
Polymer Edition, vol. 20, no. 12, pp. 1687-1707, 2012, doi: 713 
10.1163/156856208x386273. 714 
[57] R. F. B. Turner, D. J. Harrison, and R. V. Rojotte, "Preliminary in vivo 715 
biocompatibility studies on perfluorosulphonic acid polymer membranes for 716 
biosensor applications," Biomaterials, vol. 12, no. 4, pp. 361-368, 1991, doi: 717 
10.1016/0142-9612(91)90003-s. 718 
[58] M. E. Gray et al., "Biocompatibility of common implantable sensor materials in a 719 
tumor xenograft model," Journal of Biomedical Materials Research Part B: Applied 720 
Biomaterials, vol. 107, no. 5, pp. 1620-1633, 2018, doi: 10.1002/jbm.b.34254. 721 
[59] A. J. T. Teo, A. Mishra, I. Park, Y.-J. Kim, W.-T. Park, and Y.-J. Yoon, "Polymeric 722 
Biomaterials for Medical Implants and Devices," ACS Biomaterials Science & 723 
Engineering, vol. 2, no. 4, pp. 454-472, 2016, doi: 10.1021/acsbiomaterials.5b00429. 724 
[60] M. E. Gray et al., "Ovine Pulmonary Adenocarcinoma: A Unique Model to Improve 725 
Lung Cancer Research," Frontiers in Oncology, vol. 9, p. 335, 2019, doi: 726 
10.3389/fonc.2019.00335. 727 
[61] S. J. Falk, R. Ward, and N. M. Bleehen, "The influence of carbogen breathing on 728 
tumour tissue oxygenation in man evaluated by computerised pO2 histography," 729 
British Journal of Cancer, vol. 66, no. 5, pp. 919-924, 1992, doi: 730 
10.1038/bjc.1992.386. 731 
Page 24 of 36 
[62] S. Schreml, R. M. Szeimies, L. Prantl, S. Karrer, M. Landthaler, and P. Babilas, 732 
"Oxygen in acute and chronic wound healing," British Journal of Dermatology, vol. 733 
163, no. 2, pp. 257-268, 2010, doi: 10.1111/j.1365-2133.2010.09804.x. 734 
[63] J. P. R. Moore, A. Dyson, M. Singer, and J. Fraser, "Microcirculatory dysfunction and 735 
resuscitation: why, when, and how," British Journal of Anaesthesia, vol. 115, no. 3, 736 
pp. 366-375, 2015, doi: 10.1093/bja/aev163. 737 
[64] E. Maloney-Wilensky et al., "Brain tissue oxygen and outcome after severe traumatic 738 
brain injury: a systematic review," Critical Care Medicine, vol. 37, no. 6, pp. 2057-739 
63, 2009, doi: 10.1097/CCM.0b013e3181a009f8. 740 
[65] M. E. Gray et al., "In Vivo Validation of a Miniaturised Electrochemical Oxygen 741 
Sensor for Measuring Intestinal Oxygen Tension," American Journal of Physiology-742 
Gastrointestinal and Liver Physiology, vol. 317, pp. 242-252, 2019, doi: 743 
10.1152/ajpgi.00050.2019. 744 
 745 
  746 
Page 25 of 36 
 747 
 748 
 749 
Fig. 1. Personalised radiotherapy treatment concept. Miniature implantable tissue oxygen 750 
sensors (green) are implanted into a tumour (grey) containing hypoxic regions (red). Real-751 
time data from an array of implanted sensors is then used to generate a 3D map of hypoxia 752 
within the tumour. This map can inform radiotherapy (RT) dose planning and delivery, with a 753 
greater dose (blue) being directed to the hypoxic areas that are more resistant to treatment. 754 
The measurement process is then repeated using the same sensors prior to each radiotherapy 755 
fraction, enabling the treatment to be continuously personalised. 756 
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 758 
 759 
 760 
Fig. 2. Sensor electrodes and packaging. (a) Schematic cross-section through the sensor 761 
active area showing the electrode layer stack and Nafion membrane, with protective 762 
sacrificial Parylene-C and photoresist layers (dashed outline) in place prior to packaging (not 763 
to scale). (b) Photograph of a microfabricated sensor die, after removal of protective layers, 764 
showing the physical arrangement of the WE (centre disc), RE (dark middle ring), CE (outer 765 
ring), and Nafion membrane (darker circle covering electrodes). (c) Typical EDX spectra of 766 
the RE surface obtained before and after chloridisation. Characteristic X-ray energy peaks 767 
corresponding to Ag and Cl are indicated. Spectra shown are the mean of three areas on the 768 
same device. Similar results were obtained from four devices. (d) SEM images of the RE 769 
surface before (i), and after (ii) chloridisation, at higher magnification after chloridisation 770 
(iii), and in cross-section (iv) after deposition of Nafion and protective layers (asterisk 771 
indicates Ag/AgCl layer, with layers of Nafion above and silicon below). (e) Schematic 772 
cross-section through the assembled sensor packaging showing the sensor connected to a 773 
flexible PCB and encapsulated in UV cured epoxy (not to scale). (f) Photograph of a 774 
packaged sensor and its flexible PCB lead. 775 
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 776 
 777 
Fig. 3. Sensor characterisation. (a) Typical CV scans of bare and Nafion coated sensors in a 778 
solution of 1 mM potassium ferricyanide and 1 mM potassium ferrocyanide, in a 100 mM 779 
potassium chloride supporting electrolyte. Similar results were obtained from six sensors 780 
with an intact Nafion membrane, and two sensors with bare electrodes. WE potential was set 781 
against an external Ag|AgCl|KCl (3M) RE for both types of sensor. (b) Typical CV scans of 782 
a sensor in PBS saturated with air or after purging with nitrogen. The WE potential was set 783 
against the on-chip Ag/AgCl RE. Similar results were obtained from three sensors. (c) 784 
Typical CA traces from a sensor in PBS saturated with air or after purging with nitrogen, 785 
following a potential step to −0.5 V (vs on-chip Ag/AgCl RE). Similar results were obtained 786 
from four sensors. (d) Mean WE steady-state current at −0.5 V (vs on-chip Ag/AgCl RE) in 787 
PBS, measured over a range of dissolved oxygen concentrations. At each oxygen 788 
concentration 4 repeat measurements were made from each sensor (n = 4 sensors). Error bars 789 
show SD between sensors. (e) Stability of the mean WE steady-state current, measured by 790 
CA at −0.5 V (vs on-chip Ag/AgCl) in air saturated PBS. Measurements were made for 20 s, 791 
with 20 s gaps between recordings, repeated continuously (n = 8 sensors). (f) Stability of the 792 
mean on-chip RE potential (vs external Ag/AgCl) of the same sensors, measured after every 793 
tenth CA cycle for 10 s (n = 8 sensors). In both e & f the mean measurement is shown in red, 794 
and the black bands represent SD between sensors. 795 
 796 
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 797 
 798 
Fig. 4. Effect of protein biofouling and interferents on sensor performance. (a) Mean 799 
WE steady-state current at −0.5 V (vs on-chip Ag/AgCl RE) in PBS (Control) or 35 mg/mL 800 
BSA in PBS (BSA), showing effect of protein biofouling at the start (0 h) and end (24 h) of 801 
the experiment (n = 3 sensors for each condition). Error bars represent SD between sensors. 802 
(b) Mean WE steady-state current at −0.5 V (vs on-chip Ag/AgCl RE) in PBS (Cont), and 803 
PBS containing 3 µM hydrogen peroxide (HP), 375 µM urate (U), 45 µM ascorbate (A), or 804 
100 µM paracetamol (P) (n = 4 sensors for each treatment). Error bars represent SD between 805 
sensors. Statistical comparisons were made to the PBS (Control) condition.  806 
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 809 
Fig. 5. Robustness to sterilisation and irradiation. Sensors were either (i) sterilised with 810 
ethylene oxide, or (ii) exposed to four radiotherapy fractions of 6 Gy. Measurements are 811 
shown pre- and post-treatment. (a) Sensor RE potential measured against an external 812 
Ag|AgCl|KCl (3 M) RE (n = 3 sensors for each treatment). Error bars represent SD between 813 
sensors. (b) Typical CV scans in a solution of 1 mM potassium ferricyanide and 1 mM 814 
potassium ferrocyanide, in a 100 mM potassium chloride supporting electrolyte. Similar 815 
results were obtained from three sensors for each treatment. WE potential was set against an 816 
external Ag|AgCl|KCl (3M) RE. (c) Typical CV scans in PBS saturated with air. Similar 817 
results were obtained from three sensors for each treatment. The WE potential was set against 818 
the on-chip Ag/AgCl RE. (d) Mean WE steady-state current at −0.5 V (vs on-chip Ag/AgCl 819 
RE) in PBS (n = 4 sensors for each treatment). Error bars represent SD between sensors.  820 
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 822 
Fig. 6. Surgical implantation and sensor operation in lung tumour. (a) Photographs 823 
showing the procedure for surgical implantation of a sensor. (i) Insertion of a Jamshidi needle 824 
through the chest wall and into the lung tumour, (ii) introduction of the sensor and lead wire 825 
down the bore of the needle, and ejection from the needle into tumour tissue using a metal 826 
rod. (b) Typical thoracic coronal CT image (Case F1) following implantation showing sensor 827 
location (red arrow) within tumour tissue (white dashed outline). The tumour is surrounded 828 
by areas consistent in appearance with neoplastic foci or secondary pneumonia (blue dashed 829 
outline). (c) Schematic of sensor implantation and FiO2 sequence. (d) Arterial blood oxygen 830 
partial pressure at the end of each FiO2 step (n = 4 protocol repeats, from three animals). 831 
Error bars represent SD between repeats. (e) Mean sensor output at each FiO2 level, averaged 832 
over the final 5 min of the FiO2 step. The output from each sensor is plotted independently 833 
(one sensor in each of Cases F1 & F2, two sensors in Case F3).  834 
  835 
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 837 
 838 
Fig. 7. Sensor function post-implantation. (a) Photograph showing typical sensor surface 839 
contamination following recovery at post-mortem. (b) Typical pre- and post-implantation CV 840 
scans in PBS saturated with air. Similar results were obtained from four sensors. The WE 841 
potential was set against the on-chip Ag/AgCl RE. (c) Mean CA steady-state current at 842 
−0.5 V (vs on-chip Ag/AgCl RE) in PBS (n = 4 sensors). Error bars represent SD between 843 
sensors.  844 
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 849 
Supplementary Fig. S1. Nafion membrane fabrication and protection processes. 850 
Schematic cross-section through the sensor active area and adjacent packaging showing 851 
critical process steps (not to scale). For clarity, only a single set of electrode areas and a 852 
single wall of the epoxy packaging are shown. (a) Deposition and patterning of the Nafion 853 
layer to form a sensor membrane, with photoresist left in place. (b) Deposition and patterning 854 
of the Parylene-C layer to form a temporary protective barrier over the photoresist and 855 
Nafion. (c) Epoxy packaging of the sensor die, and removal of protective Parylene-C and 856 
photoresist layers.   857 
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 859 
Supplementary Fig. S2. Reference electrode sensitivity to environmental variables. 860 
(a) Mean potential of the sensor RE over a range of chloride concentrations (n = 3 sensors). 861 
Comparison between the fitted slope and an ideal Nernstian response of −58.2 mV/dec 862 
showed no significant difference (F1,10 = 0.940, p = 0.36). (b) Mean potential of the sensor 863 
RE in PBS over a range of pH values (n = 3 sensors). Comparison between the fitted slope 864 
and a flat response showed no significant difference (F1,13 = 0.310, p = 0.59). In both a & b 865 
the sensor RE was measured against an external Ag|AgCl|KCl (3 M) RE. Error bars represent 866 
the SD between sensors.  867 
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 870 
Supplementary Fig. S3. Sensor failure. Typical example of sensor failure, showing the WE 871 
steady-state current and RE potential spanning the point of RE failure (indicated by arrow) 872 
after approximately 16 h of recording in this case.  873 
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 875 
 876 
Supplementary Fig. S4. Sheep physiological observations related to hypoxia and 877 
perfusion. Observations and arterial blood analysis were performed at the end of each FiO2 878 
step (n = 4 protocol repeats from three animals). Error bars represent SD between repeats. 879 
Statistical comparisons were made to the FiO2 1.00 (Start) condition.  880 
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 883 
Supplementary Fig. S5. Real-time sensor output in tumour. Steady-state current output 884 
from sensors implanted in lung tumour tissue, showing the changes in tissue oxygenation as 885 
the fraction of inspired oxygen (FiO2) was manipulated and following euthanasia (Euth). 886 
Sensor measurements were made for 20 s, with 20 s gaps between recordings, repeated 887 
continuously throughout the experiment. Plotted values represent the mean measurement over 888 
the final 5 s of each recording, and error bars represent SD over the same period. Data are 889 
shown for all four sensors from three sheep (Cases F1 – F3) used in this experiment. 890 
